Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064

NCT03918980 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis

Interventions

DRUG: LOU064
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals